Journal Article
. 2017 Apr;8(24).
doi: 10.18632/oncotarget.16313.

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients

Jiayi Wu 1 Yan Fang 1 Lin Lin 2 Xiaochun Fei 3 Weiqi Gao 1 Siji Zhu 1 Yu Zong 1 Xiaosong Chen 1 Ou Huang 1 Jianrong He 1 Li Zhu 1 Weiguo Chen 1 Yafen Li 1 Kunwei Shen 1 
Affiliations
  • PMID: 28404972
  •     21 References
  •     10 citations

Abstract

Aim: The current study aimed to explore the distribution patterns of 21-gene recurrence score (RS) assay in Chinese early breast cancer patients.

Methods: Nine hundred and eighty consecutive estrogen receptor(ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated at Ruijin Hospital, Shanghai Jiaotong University, School of Medicine from 2009 to 2016 were retrospectively recruited. Reverse transcriptase-polymerase chain reaction (RT-PCR) assay of 21 genes were conducted in paraffin-embedded tumor tissue to calculate the RS. Co-relations of RS and clinico-pathologic factors were evaluated. Concordances of RT-PCR and immunohistochemistry (IHC) tests were measured. Logistic regression were applied to determine independent variables associated with RS.

Results: The median RS of 980 patients was 23(0~90), and the proportions of patients categorized as having a low, intermediate, or high risk were 26.1%, 49.3% and 24.6%. The distribution of RS varied significantly according to different tumor grade, T stage, progesterone receptor(PR) status, Ki67 index and molecular subtypes (p<0.05). Grade, PR status and Ki67 index were identified as independent variables associated with RS. The concordance rates between RT-PCR and IHC test were 98.8% and 88.3% for ER and PR status, and there were weak to moderate correlation between IHC and RT-PCR tests for ER, PR expression and Ki67 index.

Conclusions: RS correlated significantly with grade, T stage, PR status, Ki67 index and molecular subtypes in Chinese early breast cancer patients. Grade, PR status and Ki67 index could independently predict RS. ER, PR status and Ki67 index between RT-PCR and IHC test had remarkable concordance.

Keywords: 21-gene; breast carcinoma; clinico-pathologic factors; risk score.

Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Siobhan M O'Connor, Sushil Beriwal, David J Dabbs, Rohit Bhargava.
Appl Immunohistochem Mol Morphol, 2010 Feb 27; 18(3). PMID: 20186046
Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
John Hornberger, Michael D Alvarado, +3 authors, William J Gradishar.
J Natl Cancer Inst, 2012 Jul 07; 104(14). PMID: 22767204
Systematic Review.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
Tari A King, Jaclyn P Lyman, +17 authors, Clifford A Hudis.
J Clin Oncol, 2016 Mar 24; 34(20). PMID: 27001590    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
MiHee M Park, Joshua J Ebel, Weiquiang Zhao, Debra L Zynger.
Breast J, 2013 Nov 23; 20(1). PMID: 24261318
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Oncotype DX RT-qPCR assay for ER and PR correlation with IHC: a study of 3 different clones.
Thaer Khoury, Li Yan, Song Liu, Wiam Bshara.
Appl Immunohistochem Mol Morphol, 2014 Jul 06; 23(3). PMID: 24992175
Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
James A Kraus, David J Dabbs, Sushil Beriwal, Rohit Bhargava.
Mod Pathol, 2012 Feb 04; 25(6). PMID: 22301704
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Sunil S Badve, Frederick L Baehner, +13 authors, Joseph A Sparano.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487567
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Oleg Gluz, Ulrike A Nitz, +18 authors, Nadia Harbeck.
J Clin Oncol, 2016 Mar 02; 34(20). PMID: 26926676
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Lubna N Chaudhary, Zeeshan Jawa, +2 authors, Christopher R Chitambar.
Hematol Oncol Stem Cell Ther, 2016 Jan 26; 9(2). PMID: 26808222
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wei Wang, Xiaosong Chen, +12 authors, Kunwei Shen.
J Cancer, 2018 Oct 03; 9(18). PMID: 30271480    Free PMC article.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 Jun 02; 10. PMID: 32477946    Free PMC article.
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study.
Jiayi Wu, Shuning Ding, +16 authors, Li Zhu.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019280    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients.
Yujie Lu, Yiwei Tong, +10 authors, Kunwei Shen.
Front Oncol, 2020 Aug 28; 10. PMID: 32850415    Free PMC article.
A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
Caijin Lin, Jiayi Wu, +8 authors, Li Zhu.
Front Oncol, 2020 Oct 13; 10. PMID: 33042787    Free PMC article.
Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer.
Lauren E Arthur, Ashley H McMann, +4 authors, Ralph L Corsetti.
Ochsner J, 2021 Jan 08; 20(4). PMID: 33408575    Free PMC article.
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Peng Qi, Yu Yang, +5 authors, Xiao-Yan Zhou.
Breast Cancer Res Treat, 2021 Jan 14;. PMID: 33439420    Free PMC article.